Zentalis Pharmaceuticals, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$28.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-06
- Zentalis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$28.00K.
- Zentalis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$246.00K.
- Zentalis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $10.00K.
- Zentalis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $127.00K, a 91.27% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was -$362.00K.
- Zentalis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$1.64M, a 146.12% decline from fiscal 2023.
- Zentalis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $3.55M.
- Zentalis Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$1.23M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$28.00K 10-Q · filed 2026-08-06 | -$274.00K 10-Q · filed 2026-08-06 | -$264.00K derived: sum of 3 quarters · filed 2026-08-06 | -$137.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$246.00K 10-Q · filed 2026-05-12 | -$236.00K derived: sum of 2 quarters · filed 2026-05-12 | -$109.00K derived: sum of 3 quarters · filed 2026-05-12 | -$408.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $137.00K derived: sum of 2 quarters · filed 2026-03-26 | -$162.00K derived: sum of 3 quarters · filed 2026-08-06 | -$362.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $127.00K 10-Q · filed 2025-11-10 | -$172.00K derived: sum of 2 quarters · filed 2026-08-06 | -$372.00K 10-Q · filed 2025-11-10 | -$1.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$299.00K 10-Q · filed 2026-08-06 | -$499.00K 10-Q · filed 2026-08-06 | -$1.53M derived: sum of 3 quarters · filed 2026-08-06 | -$81.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$200.00K 10-Q · filed 2026-05-12 | -$1.24M derived: sum of 2 quarters · filed 2026-05-12 | $218.00K derived: sum of 3 quarters · filed 2026-05-12 | -$415.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $418.00K derived: sum of 2 quarters · filed 2026-03-26 | -$215.00K derived: sum of 3 quarters · filed 2026-03-26 | -$1.64M 10-K · filed 2026-03-26 |
| 2024-09-30 | $1.45M 10-Q · filed 2025-11-10 | $821.00K derived: sum of 2 quarters · filed 2025-11-10 | -$600.00K 10-Q · filed 2025-11-10 | $1.95M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-06-30 | -$633.00K 10-Q · filed 2025-08-06 | -$2.05M 10-Q · filed 2025-08-06 | $499.00K derived: sum of 3 quarters · filed 2026-03-26 | $478.00K derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-03-31 | -$1.42M 10-Q · filed 2025-05-14 | $1.13M derived: sum of 2 quarters · filed 2026-03-26 | $1.11M derived: sum of 3 quarters · filed 2026-03-26 | $1.33M derived: sum of 4 quarters · filed 2026-03-26 |
| 2023-12-31 | $2.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.53M derived: sum of 2 quarters · filed 2026-03-26 | $2.75M derived: sum of 3 quarters · filed 2026-03-26 | $3.55M 10-K · filed 2026-03-26 |
| 2023-09-30 | -$21.00K 10-Q · filed 2024-11-12 | $197.00K derived: sum of 2 quarters · filed 2024-11-12 | $994.00K 10-Q · filed 2024-11-12 | $1.91M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-06-30 | $218.00K 10-Q · filed 2024-08-09 | $1.01M 10-Q · filed 2024-08-09 | $1.93M derived: sum of 3 quarters · filed 2025-03-26 | $1.44M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-03-31 | $797.00K 10-Q · filed 2024-05-07 | $1.71M derived: sum of 2 quarters · filed 2025-03-26 | $1.22M derived: sum of 3 quarters · filed 2025-03-26 | $553.00K derived: sum of 4 quarters · filed 2025-03-26 |
| 2022-12-31 | $917.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $426.00K derived: sum of 2 quarters · filed 2025-03-26 | -$244.00K derived: sum of 3 quarters · filed 2025-03-26 | -$1.23M 10-K · filed 2025-03-26 |
| 2022-09-30 | -$491.00K 10-Q · filed 2023-11-06 | -$1.16M derived: sum of 2 quarters · filed 2023-11-06 | -$2.15M 10-Q · filed 2023-11-06 | -$2.30M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$670.00K 10-Q · filed 2023-08-09 | -$1.65M 10-Q · filed 2023-08-09 | -$1.81M derived: sum of 3 quarters · filed 2024-02-27 | -$1.87M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$984.00K 10-Q · filed 2023-05-10 | -$1.14M derived: sum of 2 quarters · filed 2024-02-27 | -$1.20M derived: sum of 3 quarters · filed 2024-02-27 | -$1.16M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$219.00K derived: sum of 2 quarters · filed 2024-02-27 | -$175.00K derived: sum of 3 quarters · filed 2024-02-27 | -$161.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | -$62.00K 10-Q · filed 2022-11-09 | -$18.00K derived: sum of 2 quarters · filed 2022-11-09 | -$4.00K 10-Q · filed 2022-11-09 | $9.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $44.00K 10-Q · filed 2022-08-09 | $58.00K 10-Q · filed 2022-08-09 | $71.00K derived: sum of 3 quarters · filed 2023-03-01 | $90.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $14.00K 10-Q · filed 2022-05-05 | $27.00K derived: sum of 2 quarters · filed 2023-03-01 | $46.00K derived: sum of 3 quarters · filed 2023-03-01 | $50.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $32.00K derived: sum of 2 quarters · filed 2023-03-01 | $36.00K derived: sum of 3 quarters · filed 2023-03-01 | $36.00K 10-K · filed 2023-03-01 |
| 2020-09-30 | $19.00K 10-Q · filed 2021-11-10 | $23.00K derived: sum of 2 quarters · filed 2021-11-10 | $23.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $4.00K 10-Q · filed 2021-08-12 | $4.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |